A computer-implemented method for predicting future operating conditions of a healthcare laboratory is provided. The healthcare laboratory contains one or more in-vitro diagnostic laboratory instruments configured to process medical samples. The method comprises: receiving medical sample event data describing events relating to one or more medical samples to be processed by the laboratory, augmenting the medical sample event data with laboratory data; creating a feature set from the augmented medical sample event data, the feature set including time bracketed data derived from the augmented medical sample event data; using the feature set as an input for a trained machine learning model, the machine learning model having been trained on historical feature sets to predict a future medical sample events within a forecast time range; and receiving, from the trained machine learning model, a prediction of future medical sample events for the forecast time range as an output.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
The invention relates to novel compounds having the general formula Ib
The invention relates to novel compounds having the general formula Ib
The invention relates to novel compounds having the general formula Ib
wherein R1, R2, R3, R4, R5 and Z are as described herein, composition including the compounds and methods of using the compounds.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positiv metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
4.
RAMAN-based method for the differentiation of AAV particle serotype and AAV particle loading status
Herein is reported a method for determining in an aqueous sample using RAMAN spectroscopy viral particles with encapsidated nucleic acids comprising the steps of providing a sample and irradiating the sample with a light source; measuring the total intensity of RAMAN scattered light of each one of a first plurality of pre-selected wavenumbers and/or wavenumber ranges to obtain a first data set for the sample; performing a first set of mathematical data processing steps on the first data set; and determining the viral particles with encapsidated nucleic acid in the sample based upon the output of the first set of mathematical data processing steps, wherein the first set of mathematical data processing steps comprises a principal component analysis and the determining is based on the first principal component.
The present invention relates to systems and methods to optimize a supply chain. Various embodiments of the present invention relate to systems and methods to optimize a multi-distribution-level supply chain and, more specifically but not limited, to systems and methods to optimize a multi-distribution-level supply chain via a machine-learning model based on reinforcement learning.
In a first aspect, the invention relates to a derivatisation agent, preferably derivatisation agent for analytes intended to be analysed via LDI-MS, comprising a structural element of formula (I) C-L1-Z-(L2)p-X, wherein C is a chromophore having an absorption maximum in the range of from 280 to 400 nm; Z is a charged unit comprising at least one permanently charged moiety; X is a reactive group; L1, L2 are each a linker unit; and p is either zero or 1.
In a first aspect, the invention relates to a derivatisation agent, preferably derivatisation agent for analytes intended to be analysed via LDI-MS, comprising a structural element of formula (I) C-L1-Z-(L2)p-X, wherein C is a chromophore having an absorption maximum in the range of from 280 to 400 nm; Z is a charged unit comprising at least one permanently charged moiety; X is a reactive group; L1, L2 are each a linker unit; and p is either zero or 1.
A second aspect of the invention is related to a kit comprising the derivatisation agent according to the first aspect. In a third aspect, the invention is directed to a use of the derivatisation agent according to the first aspect for the mass spectrometric determination of an analyte molecule, wherein the mass spectrometric determination is LDI-MS. A fourth aspect of the invention relates to a conjugate of a derivatisation agent according to the first aspect and an analyte, wherein the conjugate has the structure of formula (II) C-L1-Z-(L2)p-Xa-Ya-A, wherein C, L1, L2, p, Z and N are as defined in the context of the first aspect; Xa is a remainder of a reactive group X as defined in the context of the first aspect; A is the analyte and Ya is the remainder of a reactive group Y bound to the analyte A, which has reacted with the reactive group X of the derivatisation agent thus forming a covalent bound between Xa and Ya. A fifth aspect of the invention is related to a method for the mass spectrometric determination of an analyte molecule comprising the steps: (a) providing an analyte of interest; (b) providing a derivatisation agent comprising a structure of formula (I) as defined in the context of the first aspect; (c) reacting the analyte provided according to (a) with the derivatisation agent provided according to (b), whereby a conjugate of the analyte and the derivatisation agent is formed, and (d) subjecting the conjugate formed in (c) to a mass spectrometric analysis, wherein the mass spectrometric analysis is preferably LDI-MS.
The invention provides a compound represented by represented by the following structural formula:
The invention provides a compound represented by represented by the following structural formula:
The invention provides a compound represented by represented by the following structural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A sampling device (110) for sampling bodily fluid is proposed, comprising a stationary component (118) and a movable component (120) being movably mounted to the stationary component (118). The movable component (120) is movable from at least one distal position to at least one proximal position and back. The movable component (120) comprises at least one penetration element (132) for penetrating the skin of a user, which, in the distal position of the movable component (120), is received within the stationary component (118) and which, in the proximal position of the movable component (120), protrudes from an application side (128) of the stationary component (118). The movable component (120) comprises a container receptacle (134) for receiving at least one sample container (114) having a septum (136). The sampling device (110) further comprises a sample collection channel (138) for transporting sample from the application side (128) into the container receptacle (134). The sampling device (110) further comprises a pressure chamber (140) having a volume being dependent on the position of the movable component (120), wherein the volume when the movable component (120) is in the proximal position is smaller than the volume when the movable component (120) is in the distal position. The sampling device (110) further comprises a pressure adjustment channel (154) for transferring underpressure from the pressure chamber (140) into the sample container (114) through the septum (136) when the movable component (120) is retracted from the proximal position into the distal position. Further, a sampling kit (112) for sampling bodily fluid and a method for generating an underpressure in a sample container (114) having a septum (136) are proposed.
The disclosure is related to using machine learning algorithms to detect minimum residual disease (MRD) in cancer patients. For example, a method includes detecting somatic variants from pre-treatment samples from a patient using a variant caller. The method also includes filtering any germline mutations and sequencing artifacts from the detected somatic mutations. The method also includes classifying sequencing reads covering remaining somatic variants from the filtering using a machine learning model to identify somatic variants used for minimum residual disease (MRD) detection. The machine learning model may be trained using a random forest classifier based on a plurality of features. The method also includes analyzing the identified somatic variants to determine whether the patient is positive or negative for MRD.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The invention provides a compound represented by represented by the following strutural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
The invention provides a compound represented by represented by the following strutural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
09 - Scientific and electric apparatus and instruments
Goods & Services
Bio-sensors; biochip sensors; barcode readers; bar code
printers; portable scanners; radio-frequency identification
(RFID) tags; interfaces for computers; electronic docking
stations; application software for cloud computing services;
cases for tablet computers; cases for data storage devices;
computer software relating to the medical field; computer
software for use in medical decision support systems;
workflow management system software; software as a medical
device [SaMD], downloadable; application software for mobile
devices.
Herein is reported an immunoassay for quantifying the amount of anti-drug antibody, which anti-drug antibody can specifically bind to a drug antibody, which drug antibody can specifically bind to a therapeutic target, in a scrum or plasma sample comprising the steps of a) incubating the serum or plasma sample at a pH value that is about the pI value of the target, and optionally removing formed precipitate after the incubation, b) incubating the serum or plasma sample obtained in step a) at a pHI value of about 2, and optionally centrifuging the incubated sample to remove formed precipitate, c) adjusting the pH value to about 7.4, adding capture antibody conjugated to a first member of a binding pair and tracer antibody conjugated to a detectable label to the serum or plasma sample obtained in step b) and incubating the mixture to form a capture antibody-anti-drug antibody-tracer antibody-complex, d) quantifying the complex formed in step c) and thereby quantifying the amount of anti-drug antibody in the serum or plasma sample.
An apparatus and method for direct drug infusion from a vial to a patient are provided. A movable hanger label is provided to adhere to and support the vial to facilitate direct infusion of a drug, such as one or more pharmaceuticals, biopharmaceuticals, and/or biologics, from the vial to the patient. Additionally, a process is provided in which the drug, contained in the vial with the movable hanger label, may be directly infused through a primed infusion line with a rapid infusion rate. A saline flush is incorporated at the end of the administration to flush the infusion line, resulting in a reduced amount of the drug remaining in the line.
The present disclosure provides methods for combinatorial indexing of nucleic acids of single cells or nuclei. In particular, the methods of the present disclosure result in the incorporation of at least two index sequences within the nucleic acids of single cells or nuclei. The present disclosure further provides methods for generating and sequencing libraries of such indexed nucleic acids.
The present invention relates to methods for monitoring a subject who has been diagnosed as having or likely to have neurological motor disease or disorder, the method comprising: obtaining a pose derived from movement data comprising joint location data for a plurality of joints of the subject while performing a balance test; and determining the cosine similarity between the pose derived from the movement data and a reference pose derived from reference movement data, wherein said cosine similarity is indicative of the presence and/or severity of a neurological motor disease or disorder Related systems and clinical methods are also described.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
The invention provides compounds having the general formula (I) wherein A, X1, X2, R1, R2, R3, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with TREM2.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
20.
A DIGITAL MOTOR SCORE FOR SENSITIVE DETECTION OF HUNTINGTON'S DISEASE
The present invention relates to the field of diagnostics. Specifically, it relates to a computer-implemented method for assessing Huntington's disease (HD) in a subject comprising the steps of determining a Huntington's disease digital motor score (HDDMS) based on a multitude of digital performance features derived from at least one or more of the following: accelerometer measurements, touch sensor measurements, and/or measurements of time, in a dataset of fine motoric and motoric activity measurements from said subject; comparing the determined HDDMS to a reference; and assessing HD in the subject based on said comparison. Further, the invention contemplates a device and a system for carrying out the afore-mentioned methods and the use of such device or system for assessing Huntington's disease in the subject.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
The present invention relates to compounds of formula (I),
The present invention relates to compounds of formula (I),
wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
22.
SELECTION OF DIVERSE CANDIDATE PEPTIDES FOR PEPTIDE THERAPEUTICS
A method for developing a therapeutic such as, for example, a peptide vaccine. A machine learning model is trained using a metric learning algorithm, training peptide sequence data, and training allele presentation data corresponding to the training peptide sequence data. Peptide sequence data identifying peptide sequences that correspond to peptides is received. A peptide sequence vector is generated, via a machine learning model, for each peptide sequence using the peptide sequence data to form a plurality of peptide sequence vectors. An output is generated using the plurality of peptide sequence vectors. The output provides an indication of similarity between peptide sequences of the plurality of peptide sequences. A group of candidate peptides is selected from the plurality of peptides for development of the therapeutic based on the output such that the group of candidate peptides includes at least two dissimilar candidate peptides.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
The present invention relates to novel antibodies which bind to antigens on target cells, such as tumor cells, and which target radionuclides to said cells, to uses of those antibodies as well as methods of making them.
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
24.
CONDENSED PYRAZINES OR PYRIMIDINES ALS TREM2 AGOONISTS
The invention provides compounds having the general formula (I) or (II) (I) (II) wherein A, A1, X1, R1, R2, R3, R4, R5, and R6 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with TREM2.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Described herein are techniques of automatically extracting intervention responses of a subject from data associated with the subject. The system automatically determines time points (e.g., dates) indicating periods in which intervention responses were determined for subjects, and then uses the time points to identify datasets from which to extract intervention responses. The system extracts intervention responses of the subject from the identified datasets.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical, biochemical and biological preparations for scientific and research purposes, namely, diagnostic and detection reagents for scientific and research purposes; chemical reagents for research or laboratory use, other than for medical or veterinary use; chemical reagents for the preparation and staining of tissue specimens for research purposes; chemical reagents for non-medical purposes, namely, for use in histological and cytological tissue processing Chemical, biochemical and biological preparations for medical purposes, namely, diagnostic and detection reagents for medical use; in vitro diagnostic reagents for medical use; histology and cytology reagents and staining dyes for preparation and staining of tissue specimens for medical purposes; diagnostic reagents for medical use in the fields of pathology, immunohistochemistry and in situ-hybridization Scientific apparatus, equipment and instruments for performing analyses in laboratories, namely, automated slide staining apparatus for treating and staining tissue slide specimens for laboratory or research use; laboratory equipment, namely, automated sample handling equipment for treating and staining tissue slide specimens for diagnostic use for laboratory or research use; automated laboratory instruments, namely, slide scanners, digital imaging apparatus, microscopes and computer systems comprised of computer hardware and downloadable computer software, all for staining and visualization of tissue or cell based samples for research and scientific use; downloadable computer software for medical and diagnostic purposes, namely, for diagnosing medical disorders; downloadable computer software for the provision of automated diagnostic laboratory processes; downloadable computer software for use with laboratory instruments, namely, for use in providing remote automated control, connection, data analysis, and data management; computer systems comprised of computer hardware and downloadable software for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, for use in the fields of scientific, diagnostic and clinical research and for clinical diagnostic purposes; downloadable bioinformatics-enabled medical diagnosis software Medical apparatus and instruments for medical purposes, namely, automated slide staining apparatus for treating and staining tissue specimens for cancer and other tissue-based medical diagnostic testing; diagnostic apparatus for medical purposes, namely, sample preparation device for cancer and other tissue-based medical diagnostic testing; medical apparatus for performing in-vitro diagnostic tests for cancer and other tissue-based diseases; automated slide preparation and staining apparatus for use with tissue slide specimens for medical diagnostic use; medical apparatus and instruments for performing histological and cytological tissue processing and staining for diagnostic purposes
F. HOFFMANN-LA ROCHE AKTIENGESELLSCHAFT (Switzerland)
Inventor
Tanaka, Hiroshi
Sakata, Kiyoaki
Hasegawa, Masami
Sase, Hitoshi
Abstract
The present invention provides a drug for treating or preventing cancer, the drug comprising a compound represented by the following formula (1), a salt thereof or a solvate thereof and being used in combination with a molecular-targeted agent, wherein the molecular-targeted agent is at least one member selected from the group consisting of a KRAS-G12C selective inhibitor, a SHP2 inhibitor, a VEGF inhibitor and a PD-1 axis binding antagonist.
The present invention provides a drug for treating or preventing cancer, the drug comprising a compound represented by the following formula (1), a salt thereof or a solvate thereof and being used in combination with a molecular-targeted agent, wherein the molecular-targeted agent is at least one member selected from the group consisting of a KRAS-G12C selective inhibitor, a SHP2 inhibitor, a VEGF inhibitor and a PD-1 axis binding antagonist.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention is directed to pharmaceutical combinations for treating hepatitis B virus (HBV) infection comprising administering at least two, preferably two or three, different HBV therapeutics. In particular, the present invention relates to pharmaceutical combinations comprising an RNAi oligonucleotide targeting HBV and an anti-PDL1 antisense oligonucleotide.
A test carrier system (182) is disclosed. The test carrier system (182) comprises: at least one reaction and measurement cup (184), wherein the reaction and measurement cup (184) is configured for receiving at least one buffer solution (186), wherein the reaction and measurement cup (184) comprises at least one optical window (190) which is received in at least one wall (192) of the reaction and measurement cup (184), the optical window (192) enabling optical analysis of the buffer solution (186); and at least one sample processing unit (110), wherein the sample processing unit (110) is attachable to the reaction and measurement cup (184), wherein the sample processing unit (110) comprises: at least one sample application area (112), wherein the sample application area (112) is configured for receiving at least one sample, wherein the sample application area (112) comprises at least one capillary (114) which opens into an interior space (116) of the sample processing unit (110); and at least one chemical reagent (194), wherein the chemical reagent is received within the interior space (116) of the sample processing unit (110) or within the reaction and measurement cup (184); wherein the test carrier system (182) is configured to be rotatable around a rotation axis (196) of the test carrier system (182) whereby the buffer solution (186) is alternatively transportable to the sample application area (112) or to the chemical reagent (194) depending on at least one of a direction of rotation and a degree of rotation of the test carrier system (182) around the rotation axis (196) of the test carrier system (182).
A system and method for automated synthesis of a macromolecule from a nucleic acid template is provided, which includes a flow cell with a sipper, a mount with a thermal block, a pump, a selectable valve, a holder, an XYZ gantry, and a controller. The flow cell can be held in a fixed position while the gantry can move the holder to sippers of the flow cell. In this configuration, the sipper length can be reduced or minimized to reduce loss of precious reagents and the synthesized macromolecule.
The present invention relates to the treatment of PD-L1 -positive pancreatic cancer, e.g., PD-L1-positive pancreatic ductal adenocarcinoma (PDAC), e.g., PD-L1 -positive metastatic PDAC. More specifically, the invention pertains to the treatment of patients having a PD-L1 -positive pancreatic cancer by administering an anti-TIGIT antagonist antibody and an anti-PD-L1 antagonist antibody, e.g., by administering an anti-TIGIT antagonist antibody and an anti-PD-L1 antagonist antibody in combination with one or more chemotherapeutic agents.
A61K 31/00 - Medicinal preparations containing organic active ingredients
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention is directed to a method for determining amino acid sequence mutations in a produced polypeptide, comprising the following steps of a) providing a sample of a produced polypeptide, b) incubating the polypeptide in the sample with a protease, c) performing a two dimensional analysis using reversed phase chromatography coupled with a high resolution mass spectroscopy (FT-ICR/FT-orbitrap) and MS/MS analysis of the amino acid sequence fragments of the peptides, d) data evaluation by comparing the LC-MS data sets obtained for the samples side by side with the data set of a reference sample, by searching for differences in the signal intensities at given retention times and by evaluation of differential signals with respect to amino acid sequence mutations. The reference sample for data evaluation (d) can be either a well characterized standard or one of the samples to be analyzed.
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
33.
ESTIMATING THE ACCURACY OF AUTOMATICALLY TRANSCRIBED SPEECH WITH PRONUNCIATION IMPAIRMENTS
Systems and computer-implemented methods for determining an accuracy of automatically transcribed pathological speech comprise recording speech from a person to obtain an original speech recording; combining a perturbation with the original speech recording to obtain a perturbed speech recording; performing automatic speech recognition, ASR, on the original speech recording to obtain a first transcript; performing automatic speech recognition on the perturbed speech recording to obtain a second transcript; comparing the first transcript with the second transcript to quantify a mismatch between the first transcript and the second transcript.
The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.
Herein is reported a method for lysing recombinant AAV particle producing mammalian cells comprising the step of bringing a mammalian cell cultivation broth in contact with an alkyl polyglucoside detergent, preferably Triton CG 110, and thereby lysing recombinant AAV particle producing mammalian cells and releasing the produced recombinant AAV particles, wherein the mammalian cell cultivation broth comprises cultivated recombinant AAV particle producing mammalian cells and the cultivation medium used for the cultivation of said recombinant AAV particle producing mammalian cells (spent medium).
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and lenalidomide.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Herein is reported a method for selecting a variant of a parental antibody variable domain encoding nucleic acid, wherein the parental antibody variable domain amino acid sequence encoded by said encoding nucleic acid has at least one developability hot spot, the method comprising the steps of (i) providing a multitude of DNA-containing samples (genomic material of antibody secreting B-cell) each including one or more antibody variable domain encoding nucleic acids; (ii) performing PCR amplification of said antibody variable domain encoding nucleic acids of (i) using consensus sequence-specific primers to obtain amplification products (wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products); (iii) sequencing a plurality of said amplification products obtained in step (ii) in order to determine the relative proportion of each nucleotide at each position in a sequencing read; (iv) performing a sequence alignment between the sequencing read results of (iii) and the parental antibody variable domain encoding nucleic acid; (v) performing a sequence-identity/homology-based ranking of the antibody variable domain encoding nucleic acids in said sequence alignment with the parental antibody variable domain encoding nucleic acid being the perfect/template/reference sequence; and (vi) selecting the variant antibody variable domain encoding nucleic acid based on the sequence ranking of step (v), whereby the variant selected in step (vi) is selected so that the developability hot-spot is removed.
C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
Herein is reported a polypeptide-linker-nucleic acid conjugate, wherein the linker comprises a 3-amino propanamide unit, a 2,6-diamino hexanoic acid amide unit, and a 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit, wherein the polypeptide comprises a C-terminal lysine residue, and wherein the nucleic acid comprises an oxygen linked to a phosphorous atom of the oxidation state V at 5′ or 3′ terminus, wherein the 3-amino group of the 3-amino propanamide unit and the carboxy function of the lysine residue of the polypeptide are linked by/form an amide bond, the carboxy function of the 3-amino propanamide unit and the alpha amino group of the 2,6-diamino hexanoic acid amide unit are linked by/form an amide bond, the 6-amino group of the 2,6-diamino hexanoic acid amide unit is a nitrogen of the 1,2,3-triazole element of the 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit, and the oxygen linked to the phosphorous atom of the nucleic acid is covalently linked to the cyclopropane element of the 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A method of assessing risk of mortality of a cancer patient comprising inputting cancer patient information to a model to generate a score indicative of risk of mortality of the cancer patient, wherein the patient information includes data corresponding to one or more cancer type-specific parameters, and data corresponding to each of the following parameters: level of albumin in serum or plasma, Eastern cooperative oncology group (ECOG) performance status, ratio of lymphocytes to leukocytes in blood, smoking status, age, TNM classification of malignant tumours stage, heart rate, chloride or sodium level in serum or plasma, urea nitrogen level in serum or plasma, gender, haemoglobin or haematocrit level in blood, aspartate aminotransferase enzymatic activity level in serum or plasma, and alanine aminotransferase enzymatic activity level in serum or plasma.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
40.
COMPOSITIONS AND METHODS OF TREATING CHILDHOOD ONSET IDIOPATHIC NEPHROTIC SYNDROME
The present disclosure provides methods for treating childhood-onset idiopathic nephrotic syndrome (INS), or reducing risk and/or frequency of relapse from childhood-onset INS, in an individual that is greater than or equal to 2 years of age and less than or equal to 25 years of age. In some embodiments, the methods comprise administering to the individual an effective amount of obinutuzumab.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Described herein are techniques of automatically extracting intervention responses of a subject from data associated with the subject. The system automatically determines time points (e.g., dates) indicating periods in which intervention responses were determined for subjects, and then uses the time points to identify datasets from which to extract intervention responses. The system extracts intervention responses of the subject from the identified datasets.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
42.
Methods for Increased Pipetting Surveillance Sensitivity and Systems for Performing the Same
Described herein are methods for pipetting liquids using a pipet comprising a disposable pipet tip having a filter using pressure data calibration for improved pipetting surveillance sensitivity and/or identifying defective pipets.
Methods and systems are disclosed for performing a multiplex PCR to determine first and second target polynucleotides in a sample. The method includes (i) contacting the sample in a single container with a first probe oligonucleotide for the first target and with a second probe oligonucleotide for the second target. The first probe is labeled with a first label emitting a first label signal in a first channel, a first crosstalk signal in a second channel, and a second crosstalk signal in a third channel. The second probe is labeled with a second label emitting a second label signal in the third channel. The method further includes (ii) amplifying target polynucleotides by PCR, (iii) measuring a multitude of values in the second and third channels 10 over at least part of the amplification in step (ii), and (iv) determining the first target polynucleotide based on the values measured in step (iii).
A gripping device configured for gripping at least one includes: at least one first gripping element including at least one first contact surface for gripping the slide; at least one second gripping element, wherein the second gripping element comprises at least one second contact surface for gripping the slide, wherein the second gripping element further comprises at least two protrusions which respectively extend essentially perpendicular to the second contact surface, wherein the at least two protrusions are located on opposing ends of the second contact surface, wherein the at least two protrusions are configured for centering the slide during gripping the slide via the gripping device; wherein the first gripping element and the second gripping element are linearly movable relative to one another, wherein the first contact surface of the first gripping element and the second contact surface of the second gripping element face each other.
A port device (110) for introducing at least one liquid pharmaceutical compound into at least one intraocular space (114) is proposed. The port device (110) comprises: a. a port body (120) providing at least one channel (122) fluidically connecting at least one extraocular port (124) of the port device (110) with at least one intraocular port (126) of the port device (110); b. at least one circumferential flange (128) for attaching the port body (120) to a rim of a scleral opening (118); and c. at least one valve (134) for controlling a flow of the pharmaceutical compound through the channel (122), the valve (134) comprising at least one valve member (136) having a default closed position preventing a flow of the pharmaceutical compound through the channel (122) and an open position permitting a flow of the pharmaceutical compound through the channel (122), wherein the valve member (136) is configured to be reversibly brought from the closed position into the open position by exerting an opening force. Further, a kit (150) for introducing at least one liquid pharmaceutical compound into at least one intraocular space (114) is proposed. The kit (150) comprises at least one port device (110) according to the present invention and at least one applicator device (146). The applicator device (146) is configured to engage with the port device (110). The applicator device (146) is configured to introduce the pharmaceutical compound into the intraocular space (114) through the port device (110).
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
The present invention provides reversible fluorescent probes for cannabinoid receptor 1 ("CB1") having the general formula (I) wherein A and B are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
C09B 69/00 - Dyes not provided for by a single group of this subclass
C09B 69/10 - Polymeric dyesReaction products of dyes with monomers or with macromolecular compounds
In a first aspect, the invention relates to a filter element, preferably a blood filter element, comprising (A) a porous film, wherein the porous film comprises at least one film forming polymer and at least one film opener and is free of reactive agents; and (B) a porous support. A second aspect of the invention is directed to a process for preparing a filter element according to the first aspect. In a third aspect, the invention relates to a filter assembly, comprising (I) the filter element of the first aspect; and (II) a spreading member (C). A fourth aspect of the invention is directed to the filter element of the first aspect or the filter assembly of the third aspect, being prepared in the form of a sheet or stripe, preferably cuttable and/or punchable sheet or stripe, from which the filter element or the filter assembly is cut and/or punched in required dimensions, wherein the sheet or stripe has larger dimensions regarding length and width than the filter element or the filter assembly, allowing to cut and/or punch out at least one filter element or filter assembly, wherein in case of a filter assembly, the remaining part of spreading member (C) is optionally removed after cutting and/or punching. A fifth aspect of the invention is related to a method for preparing a filter element of the first aspect or the filter assembly of the third aspect. A sixth aspect of the invention relates to a test carrier system comprising the filter element of the first aspect, and a seventh aspect of the invention is related to a plasma separation and metering unit comprising the filter element of the first aspect. An eight aspect of the invention is directed to the use of the filter element of the first aspect or the plasma separation and metering unit of the seventh aspect for separation of blood plasma from whole blood.
B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor
A plasma separation and metering unit (110) is disclosed. The plasma separation and metering unit (110) comprises: • at least one housing (112), wherein the housing (112) comprises at least one receptacle (114) forming at least one sample port (116) for receiving at least one biological sample (168) comprising plasma (174); • at least one plasma separation element (118), wherein the plasma separation element (118) is received in the receptacle (114) of the housing (112), wherein the plasma separation element (118) comprises a sample application side (120) facing the sample port (116) and a plasma side (122) opposing the sample application side (120); and • at least one plasma metering capillary (124) extending from the housing (112), wherein an application end (126) of the plasma metering capillary (124) is fluidically connected to the plasma side (122) of the plasma separation element (118) and is configured for receiving the plasma separated from the biological sample (168) by the plasma separation element (118), wherein an outlet end (128) opposing the application end (126) of the plasma metering capillary (124) comprises an outlet opening (130), and wherein the plasma metering capillary (124) further comprises at least one lateral opening (148) in a capillary wall (132), the lateral opening (148) being located adjacent to the outlet end (128).
The present invention relates to lyo-ready biocompatible solutions and lyophilisates comprising an activeRNaseInh(-SH)n, kits comprising solutions and/or lyophilisates of the present invention and methods of producing solutions and/or lyophilisates of the present invention. The present invention further relates to the use of the herein disclosed solutions, kits and/or lyophilisates for inhibiting an RNase.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
50.
MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER
The present invention relates to compounds of formula (I),
The present invention relates to compounds of formula (I),
wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
A61K 31/504 - PyridazinesHydrogenated pyridazines forming part of bridged ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Cancer Research Technology Limited (United Kingdom)
Inventor
Amann, Maria
Karanikas, Vaios
Schnetzler, Gabriel
Foster, Kane Andrew
Ghorani, Ehsan
Quezada, Sergio
Qing, Chen
Abstract
The present disclosure is directed to the combination of a Fas axis antagonist, such as an anti-FasL antibody, and a Treg cell depletion therapy, for example an anti-CD25 antibody, optionally with a cancer vaccine, for use in the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention provides prognostic, predictive, and therapeutic methods for the treatment of rheumatoid arthritis (RA). The invention is based, at least in part, on the discovery that the expression level of one or more biomarkers described herein in a sample (e.g., a synovial tissue sample, a synovial fluid sample, or a combination thereof) from an individual having RA can be used in methods of determining whether an individual having RA is likely to exhibit disease progression, identifying an individual having RA who is likely to respond to a treatment including a disease modifying anti-rheumatic drug (DMARD), predicting responsiveness of an individual having RA to a treatment including a DMARD, selecting a therapy for an individual having RA, and treating an individual having RA, as well as related kits.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
54.
METHOD FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRAL PARTICLES
Herein is reported a method for producing a recombinant adeno-associated viral particle (rAAVp) preparation comprising the steps of cultivating a mammalian cell comprising a gene encoding a non-adeno-associated-virus gene, which is operably linked to two AAV inverted terminal repeats (ITRs) (i.e. the non-adeno-associated virus gene is interspaced between the two AAV ITRs), a gene encoding the AAV Cap protein VP1 and/or VP3, a gene encoding the AAV Rep protein Rep78 or Rep68 and/or a gene encoding the AAV Rep protein Rep52 or Rep40, a gene encoding the adenoviral helper function E4orf6, and a gene encoding the adenoviral helper function E2A, recovering the rAAVp from the cell and/or the cultivation medium, and thereby producing the rAAVp preparation, whereby the cultivating of the mammalian cell is in the presence of at least one compound selected from one of the following groups of compounds the caspase inhibitor Q-VD-OPh and IDN6556, DNA damage response activation inducing substances, including ATM/ATR inducing substances, antiviral response inhibitors, AMPK activators, oxidative phosphorylation agents, inhibitors of κB kinase, dNTP synthesis enhancers, including co-factors and building blocks, and cell cycle modulators.
The disclosure provides for methods of assessing the risks (e.g., associated with a gene therapy for the treatment of DMD (e.g., delandistrogene moxeparvovec) comprising genotyping the DMD gene and analyzing the HLA type of a subject in need of the gene therapy (e.g., delandistrogene moxeparvovec).
Herein is reported a composition for the targeted delivery of large nucleic acids to the nucleus of a eukaryotic cell comprising non-covalent complexes of histones in form of assembled nucleosomes, a large nucleic acid, a hapten, and a bispecific binder that has a first binding specificity to the hapten and a second binding specificity to a cell-surface target present on the eukaryotic cell, wherein the histone and/or the nucleic acid is/are covalently bound/conjugated to the hapten, the histone and the large nucleic acid are associated (non-covalently) with each other/form a non-covalent complex, and the hapten and the bispecific binder are associated with each other/bound to each other by the first binding specificity of the bispecific binder.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
57.
COMPUTER-IMPLEMENTED METHOD FOR DETECTING AT LEAST ONE ANALYTE IN A SAMPLE WITH A LASER DESORPTION MASS SPECTROMETER
A computer-implemented method for detecting at least one analyte in a sample with a laser desorption mass spectrometer (220) is disclosed. The method comprises:
a) at least one imaging step comprising imaging at least one reflective target (128) by using at least one imaging device (235), wherein the sample comprising the at least one analyte is applied to the reflective target (128);
b) at least one sample recognition step comprising localizing at least one sample region on the reflective target (128); and
c) at least one analyte detection step comprising detecting the at least one analyte in the sample using surface assisted laser desorption ionization mass spectrometry (SALDI-MS) with the laser desorption mass spectrometer (220), wherein laser irradiation is applied to the reflective target (128) by using at least one laser source (222) of the laser desorption mass spectrometer (220) such that at least one ion of the at least one analyte is generated which is detected by using at least one of a mass analyzing unit (224) or an ion-mobility spectrometry device of the laser desorption mass spectrometer (220), wherein the laser irradiation is steered on the localized sample region by using at least one control device (237).
The invention provides methods and compositions for treating bladder cancer (e.g., urothelial carcinoma (UC), including locally advanced or metastatic UC) in a subject, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab) and/or a platinum-based chemotherapy (e.g., cisplatin or carboplatin and gemcitabine), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating bladder cancer (e.g., UC, including locally advanced or metastatic UC) in a patient. Also provided are assays and methods for determining the presence and/or expression level of PD-L1 in a sample obtained from a patient and for labeling PD-L1 in a sample obtained from a patient.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
A method may include training a machine learning model to determine a first pharmacokinetic parameter and a second pharmacokinetic parameter for a molecule. The machine learning model may be trained by at least determining, based at least on an input including one or more pharmacokinetic models associated with the molecule, a first value of the first pharmacokinetic parameter, determining, based at least on the input, a second value of the first pharmacokinetic parameter, and determining, based at least on the first value and the second value of the first pharmacokinetic parameter, a third value of the second pharmacokinetic parameter. The method may also include applying the trained machine learning model to determine, based at least on a sparsely sampled pharmacokinetic model associated with the molecule, the first pharmacokinetic parameter and/or the second pharmacokinetic parameter. Related methods and articles of manufacture are also disclosed.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
A method may include extracting a plurality of features for each cell depicted in an image. A biomarker identification model may be applied to determine, based on the features associated with each cell, whether the cell is associated with various biomarkers. A set of probabilities for each cell in the population of cells may be determined based on an output of the biomarker identification model. The set of probabilities may include, for each biomarker, a probability of a corresponding cell being associated with the biomarker. One or more subsets of cells, each of which corresponding to a different cellular phenotype, may be identified based on the set of probabilities associated with each cell. A feature set associated with each subset of cells may be identified as being indicative of a probability of a cell being associated with a corresponding phenotype. Related systems and computer program products are also provided.
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G06V 10/40 - Extraction of image or video features
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
The present invention relates to to a computer-implemented method, a computer program, a non-transitory computer-readable storage medium, including instructions, a data processing device, and a health management device for predicting a potential effect and/or future concentration of an analyte in a bodily fluid as well as relates to a health management system for health management of a chronic disease. In order to improve health management, a subject is notified about an at least one upcoming future event and its potential effect on the analyte concentration in the bodily fluid of the subject.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
62.
TEMPERATURE MEASURING ASSEMBLY, ATTACHMENT AND SYSTEM FOR DETERMINING A TEMPERATURE INSIDE A MEDICAL CONTAINER, METHOD OF TEMPERATURE MONITORING, PROCESS VALIDATION AND/OR EQUIPMENT QUALIFICATION
The present invention relates to a temperature measuring assembly (100) for determining a temperature inside a medical container (20), the medical container (20) having a hollow body (21) with an outer body wall (22) and a body opening (23). The temperature measuring assembly (100) comprises a temperature sensor (40) comprising at least one detector element (42) having a temperature sensing portion (41), and a sensor holder (30) holding the temperature sensor (40). The sensor holder (30) is configured to be installed on the medical container (20) such that it extends through the body opening (23) into the interior of the hollow body (21) and that the temperature sensing portion (41) of the at least one detector element (42) is positioned inside the hollow body (21) at or close to the outer body wall (22) of the hollow body (21). The present invention also relates to a temperature measuring attachment (110) and a temperature measuring system (12) for determining a temperature inside a medical container (20), as well as to a method of temperature monitoring, process validation and/or equipment qualification in connection with handling temperature-controlled medical products using such a temperature measuring assembly (100), attachment (110) or system (120).
The present invention relates to compounds of formula (I),
The present invention relates to compounds of formula (I),
wherein R1 to R6, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
A61K 31/504 - PyridazinesHydrogenated pyridazines forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
65.
DOUBLE-STRANDED RNA MOLECULE FOR ADMINISTRATION TO THE EYE
The present invention relates to double-stranded RNA molecules conjugated to at least one conjugate moiety for topical administration to the eye, and pharmaceutical compositions thereof. The double-stranded RNA molecules are complementary, such as fully complementary, to targets expressed in the eye, and are capable of inhibiting expression of targets expressed in the eye. The double-stranded RNA molecules can be used in the treatment of conditions and diseases of the eye.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates to the simultaneous imaging of nucleic acids and proteins in a sample. In particular, the present disclosure provides compositions, methods, systems and kits for imaging at least one target protein and at least one target nucleic acid in a single sample.
Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Hbb]pyrazine compound of formula (I), or a stereoisomer thereof: Formula (I), or a pharmaceutically acceptable salt thereof; and compounds prepared by these processes.
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present invention provides antibodies specifically binding to Pepsinogen A and compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such antibodies, host cells expressing said antibodies, methods of producing such antibodies and diagnostic methods using such antibodies.
The present invention discloses a new gene fusion which is characteristic for Non- small-cell lung cancer cells and can this be used for specific detection for of Non- small-cell lung tumors.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
74.
METHODS AND MATERIALS FOR MEASURING COMPLEMENT ACTIVATION
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
75.
DATA-INDEPENDENT ACQUISITION (DIA) FOR MASS SPECTROMETRIC ANALYSIS OF MHC PEPTIDES
e.g.e.g., a patient sample). In some instances, for example, the methods can comprise: predicting, using one or more machine-learning models, an MHC allele-specific mass spectral library for the sample; performing a mass spectrometric analysis of peptides extracted from the sample using data-independent acquisition (DIA) to generate mass spectral data for the peptides; and performing a spectral library search using the mass spectral data for the peptides and the predicted MHC allele-specific mass spectral library for the sample to identify at least one MHC peptide present in the sample.
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; biological preparations,
other than for medical or veterinary purposes; biochemical
preparations for scientific purposes; diagnostic reagents
for scientific or research use; reagents for use in
scientific apparatus for chemical or biological analysis;
chemical preparations for analyses in laboratories, other
than for medical or veterinary purposes; nucleic acids for
scientific purposes; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology; chemical
reagents for use in genetic research.
77.
METHOD TO ANALYZE AND OPTIMIZE GENE EDITING MODULES AND DELIVERY APPROACHES
Herein is reported a method for determining the introduction of a nucleic acid into the genome of a mammalian cell, whereby the mammalian cell comprises one or two transcriptionally active alleles of a DPH1, DPH2, DPH4 and/or DPH5 gene, comprising the steps of transfecting the mammalian cell with one or more plasmids comprising the nucleic acid to be introduced, and the elements required for gene editing of said DPH gene, cultivating the transfected cell in the presence of a DPH gene transcription sensitive toxin, and thereby determining the introduction of a nucleic acid into the genome of the mammalian cell if the transfected cells is viable in the presence of the toxin.
A method may include receiving a molecular structure file specifying an initial three-dimensional structure of a molecule. A representation of the molecule may be determined based on the molecular structure file. For example, the representation of the molecule may include a plurality of coarse-grained nodes, each corresponding to a structural body of two or more atoms (e.g., heavy atoms) forming an amino acid residue in the molecule. Alternatively, the representation of the molecule may include, for each residue in the molecule, a plurality of frames specifying a geometric state of the backbone of the residue and one or more torsion angles in the sidechain of the residue. A design computation model may be applied to determine a three-dimensional structure of the molecule by at least modifying the representation of the molecule. The three-dimensional structure may be associated with a desirable property and/or be configured for a downstream task.
G16B 45/00 - ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
79.
IN VITRO DIAGNOSTIC TEST SYSTEM, IVD TEST APPARATUS AND A METHOD OF PERFORMING A MULTIPLEXED DIAGNOSTIC ASSAY AT AN IMPROVED DEGREE OF EFFICIENCY AND ECO-FRIENDLINESS
The invention allows an increased throughput of diagnostic assays and doubles, triples or even further increases the number of assays per cartridge and may therefore be considered as very environmental- and eco-friendly. At the same time, multiple potentially life-saving test results may be provided for one or more patients. The invention relates to an In Vitro diagnostic (IVD) test system (1a, 1b) for performing a multiplexed diagnostic assay, wherein the IVD test system (1a, 1b) comprises: a test carrier (2) comprising a sample application port (3) configured to receive a sample fluid (30); a test zone (4) comprising a shared recessed assay membrane area (4a) and a sample release port (4b) for releasing at least one portion (30, 30a) of the sample fluid (30) to the shared recessed assay membrane area (4a); and a microfluid sample channel system (5) configured to guide the at least one portion (30, 30a) of the sample fluid (30) from the sample application port (3) to the sample release port (4b); the IVD test system (1a, 1b) further comprising: a first assay membrane (6) positioned in the shared recessed assay membrane area (4a) and configured to receive a first part of the at least one portion (30, 30a) of the sample fluid (30) from the sample release port (4b) and to indicate at least one first analyte (31a) in the first part of the at least one portion (30, 30a) of the sample fluid (30); and a second assay membrane (7) positioned in the shared recessed assay membrane area (4a) next to the first assay membrane (6) and configured to receive a second part of the at least one portion (30, 30a) of the sample fluid (30) from the sample release port (4b) and to indicate at least one second analyte (31b) in the second part of the at least one portion (30, 30a) of the sample fluid (30) and/or to indicate the at least one first analyte (31a) in the second part of the at least one portion (30, 30a) of the sample fluid (30) in a different sensitivity range as the first assay membrane (6).
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
80.
TWO NOVEL FUSION TRANSCRIPTS FOR EARLY DETECTION OF NON-SMALL-CELL LUNG CANCER (NSCLC)
The present invention provides a new gene fusion of TPTE2 and MRPS31P2 which is characteristic for Non-small-cell lung cancer cells and can be used for specific detection of Non-small-cell lung tumors.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
e.g.e.g.e.g., tuberculosis, leprosy, nontuberculous mycobacterial infections, or a combination thereof). Pharmaceutical compositions comprising said compounds are also provided.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
chemical, biological and biochemical preparations for scientific and research purposes; chemical substances for analyses in laboratories, not for medical or veterinary purposes; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology research; biochemical preparations, namely, recombinant human enzymes, for scientific and research purposes; chemical reagents for molecular biology, not for medical or veterinary use chemical, biological and biochemical preparations for medical purposes; in vitro diagnostic reagents for medical purposes; chemical substances for analyses in laboratories for medical purposes; reagents for in-vitro laboratory use for medical purposes; chemical preparations containing enzymes for medical purposes; biochemical preparations, namely, recombinant human enzymes for medical purposes
The present invention provides methods to prevent the formation of visible particles in aqueous protein formulations, as well as compositions and pharmaceutical products obtained with said method.
The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G06F 16/28 - Databases characterised by their database models, e.g. relational or object models
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
86.
CROSS-MODALITY PIXEL ALIGNMENT AND CELL-TO-CELL REGISTRATION ACROSS VARIOUS IMAGING MODALITIES
A method implemented by one or more computer devices includes receiving a plurality of images of a set of tissue cells, the plurality of images comprising a first image including a first visualization modality and a second image including a second visualization modality. The method includes identifying a first tissue cell of the set of tissue cells in the first image and the first tissue cell in the second image, and performing a cell-to-cell registration process based on the first tissue cell identified in the first image and the first tissue cell identified in the second image. The cell-to-cell registration process includes matching of the first tissue cell identified in the first image to the first tissue cell identified in the second image. The method includes classifying the first tissue cell into a phenotype based on the cell-to-cell registration process, the phenotype partially indicative of a disease pathology.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
87.
SPACETIME ATTENTION FOR CLINICAL OUTCOME PREDICTION
A disease prognosis model to may be trained to determine the clinical outcome of a disease based on longitudinal data including a health record for each timepoint in a sequence of timepoints. The disease prognosis model may include a recurrent neural network trained to extract, from each health record, a feature set representative of local dependencies present within the health record. The disease prognosis model may include a spacetime attention trained to determine an importance of each feature in the feature set at each timepoint in the sequence of timepoints. The disease prognosis model may include a feedforward neural network trained to determine, based on the importance of each feature in the feature set at each time point in the sequence of timepoints, the clinical outcome of the disease. The trained disease prognosis model may be applied to determine the clinical outcome of the disease for one or more patients.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
88.
TARGET ENRICHMENT BY UNIDIRECTIONAL DUAL PROBE PRIMER EXTENSION
The present disclosure provides a method for enrichment of at least one target nucleic acid in a library of nucleic acids. A first oligonucleotide is hybridized to a target nucleic acid in library of nucleic acids having first and second adapters. The hybridized first oligonucleotide is extended with a first polymerase, thereby producing a first primer extension complex including the target nucleic acid and the extended first oligonucleotide. The first primer extension complex is captured, enriched relative to the library of nucleic acids, and a second oligonucleotide is hybridized to the target nucleic acid. The hybridized second oligonucleotide is extended with a second polymerase, thereby producing a second primer extension complex including the target nucleic acid and the extended second oligonucleotide and further liberating the extended first oligonucleotide from the first primer extension complex.
A biomedical knowledge graph system includes a computer database of records comprising nodes of biomedical entities and connections between the entities representing biomedical relationships. One or more processors are configured to extract data from a plurality of data sources and determine biomedical entities and relationships between the entities based on analyzing the data, including searching for predetermined identifiers or patterns in the data. Based on the determined biomedical entities, each biomedical entity is assigned to a cluster of biomedical entity types and a context is identified for each of the entities. Based on the identified context and type of the biomedical entity, records of nodes and connections between nodes are incorporated into the knowledge graph, the nodes representing biomedical entities and the connections representing biomedical relationships between the entities structured according to the predefined schema.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Computer-implemented methods of providing a clinical predictor tool are described, comprising: obtaining training data comprising, for each of a plurality of patients, values for a plurality of clinical variables comprising a variable indicative of a diagnosis or prognosis and one or more further clinical variables; and training a clinical predictor model to predict the variable indicative of a diagnosis or prognosis using said training data, wherein obtaining the training data comprises obtaining synthetic clinical data comprising values for a plurality of clinical variables for one or more patients by obtaining a directed acyclic graph (DAG) edges corresponding to conditional dependence relationships inferred from real clinical data comprising values for the plurality of clinical variables for a plurality of patients, and obtaining values for each node of the DAG using a machine learning model and multivariate conditional probability table. Computer-implemented methods of obtaining synthetic clinical data are also described.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
91.
PREDICTING TILE-LEVEL CLASS LABELS FOR HISTOPATHOLOGY IMAGES
A method implemented by one or more computer devices includes providing weakly-supervised neural networks for analysis of histopathology images. The method includes accessing a histopathology image including a slide-level class label. The method includes extracting a plurality of regions of pixels of the histopathology image at a plurality of magnifications. For each of the extracted plurality of regions of pixels, the method further includes inputting the region of pixels into a machine-learning model trained to generate a prediction of a class label for the region of pixels based on the region of pixels and the slide-level class label and outputting the prediction of the class label for the region of pixels. The method includes generating a prediction of one or more tile-level class labels for the histopathology image based on the predictions of class labels for each of the extracted plurality of regions of pixels.
The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
In one embodiment, a method includes accessing a biomolecule representation of a first biomolecule and processing the biomolecule representation by a machine-learning model trained using sequencing time-series data. The sequencing time-series data was obtained from directed evolution of a population of biomolecules over multiple enrichment rounds where the population of biomolecules in each enrichment round was a unique set of biomolecules with respect to each other enrichment round. The sequencing time-series data for each enrichment round comprises a biomolecule frequency of each biomolecule of the population of biomolecules in the respective enrichment round. The training comprises learning inferred fitness scores of the population of biomolecules for each enrichment round by predicting biomolecule frequencies of the population of biomolecules in the respective enrichment round given biomolecule frequencies of the population of biomolecules in prior enrichment rounds. The method further includes outputting an inferred fitness score for the first biomolecule.
The present invention relates to the field of polypeptide conjugates, more in particular to conjugates comprising a polypeptide, a nucleic acid and a linker, wherein the conjugation involves a click chemistry between an organic azide and dibenzocyclooctine (DBCO) derivatives. The invention relates as well to methods to obtain such conjugates, as well as to their use in the treatment of a neurological disease, a brain disease, or cancer.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A computer-implemented method for controlling a mass spectrometry analyzer system (110) for analysis of an analyte of interest is proposed. The mass spectrometry analyzer system (110) comprises at least one sample preparation unit, at least one liquid chromatography (LC) unit and at least one mass spectrometer (MS) analyzer unit. The method comprises automatically performing the following steps a) providing at least one experimental plan for at least one unit of the mass spectrometry analyzer system, wherein the experimental plan comprises at least one initial parameter set considering initial knowledge of at least one knowledge database, wherein the initial parameter set comprises at least one control parameter used for performing at least one measurement for analysis of the analyte of interest on said unit, wherein the experimental plan comprises scanning at least partially a parameter space of the control parameter; b) transferring the experimental plan into control instructions for said unit; c) executing the control instructions on said unit, thereby performing at least one measurement in accordance with the experimental plan and obtaining at least one measurement result; d) evaluating the measurement result obtained in step c), wherein the evaluating comprises optimizing the initial parameter set in view of the measurement result, thereby determining an optimized parameter set; and e) storing and/or updating the optimized parameter set in the knowledge database.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Biological preparations, other than for medical or veterinary purposes; Biochemical preparations for scientific purposes; Diagnostic reagents for scientific or research use; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Chemical preparations for scientific purposes, other than for medical or veterinary use. Chemical preparations for medical purposes; Biochemical preparations for medical use; In vitro diagnostic preparations for medical use; Diagnostic reagents for medical use; Reagents for in-vitro laboratory use [for medical purposes]; Biological preparations for medical purposes.
09 - Scientific and electric apparatus and instruments
Goods & Services
(1) Bio-sensors; biochip sensors; barcode readers; bar code printers; portable scanners; radio-frequency identification (RFID) tags; interfaces for computers; electronic docking stations; application software for cloud computing services; cases for tablet computers; cases for data storage devices; computer software relating to the medical field; computer software for use in medical decision support systems; workflow management system software; software as a medical device [SaMD], downloadable; application software for mobile devices.
09 - Scientific and electric apparatus and instruments
25 - Clothing; footwear; headgear
28 - Games; toys; sports equipment
Goods & Services
Vêtements de protection contre les accidents; dispositifs électroniques de déclenchement de matériel de sécurité et de matériel de protection contre les accidents; renforts de protection pour le dos, le thorax, les épaules, les coudes et les genoux, pour la protection contre les accidents; vêtements, chaussures, gants et casques de protection; lunettes, lunettes de soleil, montures de lunettes, verres de lunettes et étuis à lunettes; visières anti-éblouissantes. Casques de protection pour la pratique des deux, trois ou quatre roues et pour la pratique des sports mécaniques deux, trois ou quatre roues; visières de casques; parties de vêtements de protection contre les accidents ou les blessures à savoir rembourrages de protection et de sécurité pour la pratique des deux, trois ou quatre roues; protèges genoux et protèges coudes contre les accidents ou les blessures pour la pratique des deux, trois ou quatre roues. Vêtements, vêtements en cuir; vêtements de sport, vêtements d’équitation; blousons et vestes textiles, gilets, sweatshirts, t-shirts, pantalons; chemises; ceintures (habillement); fourrures (vêtements); gants (habillement); foulards; chapellerie; bonneterie; casquettes; bonnets; bandanas; chaussettes; chaussons; chaussures; chaussures de sport, sous-vêtements. Rembourrages de protection pour la pratique de sports, rembourrages de protection en tant que parties d'habillement de sport, protège-hanches, protège-dos pour le sport, dispositifs de protection dorsale, ceintures protège-taille pour le sport, protège-tibias, protège-chevilles, protège-genoux, protège-jambes pour le sport, protège-coudes, protège-mains, protège-poignets, protèges-épaules (articles de sport), protège-cou pour le sport, tenues de protection (pour le sport), gants de protection (pour le sport), sacs conçus pour le transport d'équipements de sport.
